SUMMIT THERAPEUTICS INC (SMMT)
US86627T1088 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 860K -98.49% | 1.81M 110.47% | 710K -60.77% | N/A -100.00% | -14.469M | 190M 1,413.18% | 847.65M 346.13% | 2.089B 146.45% | 3.774B 80.66% | 5.54B 46.79% | 7.579B 36.81% | |||
| EBITDA YoY % growth | -50.78M -488.82% | -84.84M -67.07% | -62.36M 26.50% | N/A -41.98% | -224.001M -153.00% | -277.746M -23.99% | -312.022M -12.34% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -52.33M -563.51% | -86.19M -64.70% | -63.62M 26.19% | N/A -39.48% | -224.805M -153.34% | -303.893M -35.18% | -471.146M -55.04% | -462.252M 1.89% | 264.67M 157.26% | 1.627B 514.73% | 3.389B 108.30% | 5.725B 68.93% | 7.448B 30.10% | |
| Operating Margin | -6,084.88% | -4,761.88% | -8,960.56% | N/A | N/A | N/A | 3,256.31% | -243.29% | 31.22% | 77.88% | 89.80% | 103.34% | 98.27% | |
| EPS YoY % growth | -3.39 | N/A | N/A | N/A | -0.30 -98.22% | -0.42 -41.11% | -0.61 -46.11% | -0.55 9.48% | 0.42 175.92% | 2.05 385.47% | 3.86 88.94% | 7.29 88.56% | 9.04 24.11% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.08 -96.99% | -0.08 -36.00% | -0.09 -2.00% | -0.10 -27.50% | -0.12 -51.03% |
| Revenue Q2Q % growth | -100.00% | ||||
| EBITDA Q2Q % growth | -60.368M -67.63% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -59.084M -63.17% | -60.486M -48.25% | -62.858M -33.97% | -65.28M -11.82% | -69.87M -18.26% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.08 -166.67% | -0.07 | -0.01 | -17.64% |
| Q2 2024 Q2Q % growth | -0.09 -350.00% | -0.06 | -0.03 | -42.31% |
| Q1 2024 Q2Q % growth | -0.06 | -0.06 | 0.00 | 1.96% |
| Q4 2023 Q2Q % growth | -0.04 42.86% | % | ||
| Q3 2023 Q2Q % growth | -0.03 78.57% | % | ||
| Q3 2022 Q2Q % growth | -0.14 86.00% | % | ||
| Q3 2021 Q2Q % growth | -1.00 19.35% | -0.30 | -0.70 | -238.07% |
| Q2 2021 Q2Q % growth | 99.77% | 0.00 | % | |
| Q1 2021 Q2Q % growth | -1.05 -950.00% | 0.00 | -1.05 | -39,799.68% |
| Q4 2020 Q2Q % growth | -0.90 | 0.00 | -0.90 | -40,006.95% |
| Q3 2020 Q2Q % growth | -1.24 | -0.01 | -1.23 | -10,852.13% |
| Q2 2020 Q2Q % growth | -1.15 | -0.02 | -1.13 | -5,537.25% |
| Q1 2020 Q2Q % growth | -0.10 | -0.02 | -0.08 | -390.20% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -100.00% | % | ||
| Q3 2023 Q2Q % growth | 270K 22.73% | % | ||
| Q2 2023 Q2Q % growth | -100.00% | % | ||
| Q1 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | -100.00% | % | ||
| Q3 2022 Q2Q % growth | 220K -83.21% | % | ||
| Q2 2022 Q2Q % growth | 240K 300.00% | % | ||
| Q1 2022 Q2Q % growth | 250K 31.58% | % | ||
| Q4 2021 Q2Q % growth | 250K 31.58% | % | ||
| Q3 2021 Q2Q % growth | 1.31M 627.78% | 1.31M | % | |
| Q2 2021 Q2Q % growth | 60K -64.71% | 4.518M | -4.458M | -98.67% |
| Q1 2021 Q2Q % growth | 190K -40.63% | 4.495M | -4.305M | -95.77% |
| Q4 2020 Q2Q % growth | 190K | 3.913M | -3.723M | -95.14% |
| Q3 2020 Q2Q % growth | 180K 20.00% | 4.041M | -3.861M | -95.55% |
| Q2 2020 Q2Q % growth | 170K 6.25% | 4.59M | -4.42M | -96.30% |
| Q1 2020 Q2Q % growth | 320K -34.69% | 5.171M | -4.851M | -93.81% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -18.85% | 3.56% | -6.52% |
| Revenue | N/A | N/A | N/A | N/A |